Precision reports initial outcomes from Hepatitis B trial of PBGENE-HBV

Precision BioSciences has reported initial outcomes from the ELIMINATE-B trial of PBGENE-HBV, a gene editing programme for treating chronic Hepatitis B patients who are HBeAg-negative.